Success Story

Abrax Japan licenses technology from Penn Medicine

Abrax Japan entered into an exclusive licensing agreement for certain Penn-owned inventions relating to the therapeutic effects of thymic stromal lymphopoietin (TSLP) developed by company co-founder Dr. Taku Kambayashi, an Associate Professor of Pathology and Laboratory Medicine at Penn Medicine. Under the terms of the agreement, Abrax Japan has secured exclusive global rights to these intellectual property assets for two specific fields of use: i) treatment and/or prevention of skin and scalp ailments and disorders, including, but not limited to eczema, alopecia, dry skin, aging skin, acne, and ichthyoses; and ii) treatment and/or prevention of lipid metabolism disorders, including, but not limited to hypercholesterolemia, hypertriglyceridemia, and obesity.

Skip to content